Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Northwest Biotherapeutics has the GF Score of 17, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Northwest Biotherapeutics
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Northwest Biotherapeutics GF Score Related Terms
STU:NBYB vs LCTX, VRXA, ABEO: GF Score Comparison
For the Biotechnology subindustry, Northwest Biotherapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Northwest Biotherapeutics GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's GF Score distribution charts can be found below:
* The bar in red indicates where Northwest Biotherapeutics's GF Score falls into.
Northwest Biotherapeutics (STU:NBYB) has a GF Score of 17 as of Jul. 21, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Northwest Biotherapeutics and its competitors. This is 29% below median its historical median of 24.00. Over the past decade, Northwest Biotherapeutics' GF Score has ranged from 2.00 to 42.00.
Is Northwest Biotherapeutics' GF Score too high?
Northwest Biotherapeutics' current GF Score of 17 is 29% below median its 10-year median of 24.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 42.00. Overall, Northwest Biotherapeutics has a GF Score™ of 17/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Northwest Biotherapeutics' GF Score compare to LCTX and VRXA?
Northwest Biotherapeutics' GF Score of 17 can be compared against companies in the Biotechnology industry. Historically, Northwest Biotherapeutics' own GF Score has ranged from 2.00 to 42.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Northwest Biotherapeutics and its competitors. Northwest Biotherapeutics's current GF Score is 17, which is 29% below median its own 10-year median of 24.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northwest Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Northwest Biotherapeutics (STU:NBYB) is currently considered Possible Value Trap. The stock's GF Value™ is €0.24, compared to a current price of €0.15 — trading 37.5% below its estimated fair value. The current GF Score is 17, which is 29% below median its 10-year median of 24.00. Northwest Biotherapeutics' overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Northwest Biotherapeutics (STU:NBYB), the current GF Score is 17 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Northwest Biotherapeutics (STU:NBYB) Overvalued in 2026?
Based on GuruFocus' analysis, Northwest Biotherapeutics stock appears to be undervalued.
The current stock price of €0.15 is trading 37.5% below its estimated GF Value™ of €0.24.
GuruFocus considers Northwest Biotherapeutics to be Possible Value Trap.
Key valuation signals for STU:NBYB:
GF Score: 17 (29% below median its 10-year median of 24.00)
GF Value™: €0.24 vs. price of €0.15 (37.5% below fair value)
No single metric tells the full story. See the STU:NBYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
17GF Score
Get the complete analysis for STU:NBYB
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:NBYB has been successfully added to your 
